Jonathan Croopnick, MD
Hematology & Oncology · Foxboro, MANPI 1598871360
Payments from drug & device makers
Across 158 payments — averaging $36.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rigel Pharmaceuticals, Inc.$1K
- Myriad Genetic Laboratories, Inc.$1K
- Astellas Pharma US Inc$681
- Johnson & Johnson$316
- E.r. Squibb & Sons, L.L.C.$219
- Pharmacyclics LLC, An Abbvie Company$172
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$1,17020%
- Food & beverage$3,48460%
- Education$1,14020%
- Other$291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rigel Pharmaceuticals, Inc. | 4 | $1,357 |
| Myriad Genetic Laboratories, Inc. | 31 | $1,226 |
| Astellas Pharma US Inc | 8 | $681 |
| Johnson & Johnson(2 entities) | 15 | $316 |
| E.r. Squibb & Sons, L.L.C. | 12 | $219 |
| Pharmacyclics LLC, An Abbvie Company | 6 | $172 |
| Merck | 8 | $164 |
| AstraZeneca | 4 | $154 |
| Bristol Myers Squibb | 5 | $151 |
| Array Biopharma Inc | 6 | $127 |
| Amgen | 5 | $114 |
| Seagen Inc. | 6 | $107 |
| Pfizer | 6 | $105 |
| Eisai Inc. | 6 | $104 |
| Incyte Corporation | 4 | $92 |
| AbbVie | 1 | $83 |
| Taiho Oncology, Inc. | 4 | $77 |
| GSK | 4 | $71 |
| CSL Behring | 2 | $60 |
| Genentech USA, Inc. | 3 | $54 |
| Daiichi Sankyo Inc. | 2 | $47 |
| Acrotech Biopharma Inc. | 2 | $34 |
| Exelixis Inc. | 1 | $31 |
| Organon | 1 | $30 |
| Welch Allyn | 1 | $29 |
| Karyopharm Therapeutics Inc. | 1 | $28 |
| Mirati Therapeutics, Inc. | 1 | $25 |
| AMAG Pharmaceuticals, Inc. | 1 | $24 |
| Boehringer Ingelheim | 1 | $24 |
| Novartis | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $21 |
| Progenics Pharmaceuticals, Inc. | 1 | $18 |
| CTI Biopharma Corp. | 1 | $18 |
| Ipsen Biopharmaceuticals, Inc | 1 | $15 |
| ADC Therapeutics America, Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tavalisse$1,321
- myChoice CDx$207
- PreciseTumor$110
How this compares
$5,824 in reported general payments places this provider in the 45th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lenalidomide | 51 | $761,029 |
| ImbruvicaIbrutinib | 30 | $473,082 |
| IbrancePalbociclib | 24 | $383,859 |
| XtandiEnzalutamide | 27 | $380,028 |
| OjjaaraMomelotinib Dihydrochloride | 12 | $341,601 |
| TagrissoOsimertinib Mesylate | 18 | $278,053 |
| EliquisApixaban | 96 | $109,792 |
| SprycelDasatinib | 11 | $108,933 |
| XareltoRivaroxaban | 48 | $71,987 |
| Imatinib Mesylate | 33 | $69,017 |
| Abiraterone Acetate | 17 | $45,263 |
| Anastrozole | 197 | $6,293 |
| Hydroxyurea | 50 | $1,796 |
| Letrozole | 50 | $1,496 |
| Tamoxifen Citrate | 25 | $1,147 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $105 | $493,651120 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $172 | $473,08230 claims |
| Astellas Pharma US IncXtandi | $681 | $380,02827 claims |
| GSKOjjaara | $71 | $341,60112 claims |
| AstraZenecaTagrisso | $154 | $278,05318 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $219 | $108,93311 claims |
| Johnson & JohnsonXarelto | $316 | $71,98748 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 374 hematology & oncology providers in Massachusetts.
Other hematology & oncology in Foxboro
- Matthew DavidsBoston$58.6M
- Nadine TungBoston$32.4M
- Jorge CastilloBoston$31.2M
- Daniel DeangeloBoston$28.5M
- Sara TolaneyBoston$20.3M
- Austin KimWorcester$19.3M
- Paul RichardsonBoston$17.2M
- Amir FathiBoston$14.8M
- Jacqueline GarciaBoston$13.6M
- Jacob SandsBurlington$13.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.